A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior

Ingrid Ehrmann, Matthew Gazzara, Vittoria Pagliarini, Caroline Dalgliesh, Mahsa Kheirollahi-Chadegani, Yaobo Xu, Eleonora Cesari, Marina Danilenko, Marie Maclennan, Kate Lowdon, et al.

To cite this version:

Ingrid Ehrmann, Matthew Gazzara, Vittoria Pagliarini, Caroline Dalgliesh, Mahsa Kheirollahi-Chadegani, et al.. A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior. Cell Reports, Elsevier Inc, 2016, 17 (12), pp.3269-3280. 10.1016/j.celrep.2016.12.002. hal-02267220

HAL Id: hal-02267220
https://hal.archives-ouvertes.fr/hal-02267220
Submitted on 30 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior

Highlights
- SLM2 splicing targets are spatially controlled within the hippocampus
- RNA-seq reveals SLM2 feedback control and synaptic protein splicing targets
- Loss of SLM2 dampens patterns of hippocampal γ oscillations
- Loss of SLM2 changes mouse behavior that depends on these neural networks

Authors
Ingrid Ehrmann, Matthew R. Gazzara, Vittoria Pagliarini, ..., Yoseph Barash, Mark O. Cunningham, David J. Elliott

Correspondence
gavin.clowry@ncl.ac.uk (G.J.C.), yosephb@upenn.edu (Y.B.), mark.cunningham@ncl.ac.uk (M.O.C.), david.elliott@newcastle.ac.uk (D.J.E.)

In Brief
SLM2 is an RNA binding protein conserved for ~550 million years. Ehrmann et al. identify a homeostatic feedback pathway that controls SLM2 expression across the brain. Loss of SLM2 protein causes defects in neural network activity and changes mouse behavior.

Accession Numbers
GSE70895
A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior

Ingrid Ehrmann, Matthew R. Gazzara, Vittoria Pagliarini, Caroline Dalgliesh, Mahsa Kheirollahi-Chadegani, Yaobo Xu, Eleonora Cesar, Marina Danilenko, Marie Maclennan, Kate Lowdon, Tanja Vogel, Piia Keski-Vali Bond, Sara Wells, Heather Cater, Philippe Fort, Mauro Santibanez-Koref, Silvia Middei, Claudio Sette, Gavin J. Clowry, Yoseph Barash, Mark O. Cunningham, and David J. Elliott

SUMMARY

The brain is made up of trillions of synaptic connections that together form neural networks needed for normal brain function and behavior. SLM2 is a member of a conserved family of RNA binding proteins, including Sam68 and SLM1, that control splicing of Neurexin1-3 pre-mRNAs. Whether SLM2 affects neural network activity is unknown. Here, we find that SLM2 levels are maintained by a homeostatic feedback control pathway that predates the divergence of SLM2 and Sam68. SLM2 also controls the splicing of Tomosyn2, LysoPLD/ATX, Dgkb, Kif21a, and Cask, each of which are important for synapse function. Cortical neural network activity dependent on synaptic plasticity is decreased in Slm2-null mice. Additionally, these mice are anxious and have a decreased ability to recognize novel objects. Our data reveal a pathway of SLM2 homeostatic auto-regulation controlling brain network activity and behavior.

INTRODUCTION

Alternative splicing expands the coding information in the genome many fold. More than 95% of human genes encode alternative mRNAs, and on average each human gene makes 11 different mRNAs (Djebari et al., 2012). Alternative splicing is controlled by a large set of ubiquitous, as well as tissue-specific RNA binding proteins and is functionally important in the brain and across development (Kalsotra and Cooper, 2011). Genetic knockout of some splicing regulators can cause catastrophic phenotypic effects on brain development (Gehman et al., 2012), and even subtle defects in splice factors have been linked with diseases such as autism and neurodegeneration (Voineagu et al., 2011). SLM2 is a tissue-specific RNA binding protein expressed at high levels in the brain and is related to the Sam68 and SLM1 RNA binding proteins following a gene triplication 500 million years ago. Both SLM2 and Sam68 bind to UA-rich target sequences (UAAA and UUAA) (Feracci et al., 2016). Analysis of the transcriptome of whole mouse brain (Ehrmann et al., 2013) and whole hippocampus (Traumuller et al., 2016) showed that SLM2 regulates skipping of the Neurexin1-3 AS4 exons and a cassette exon within Tomosyn-2 (Stxbp5).

The Neurexin-1-3 proteins are important for synapse formation, maturation, and function in the brain, where they play a critical role in stabilizing the trans-synaptic complex, and help generate and maintain communication at both glutamatergic and GABA (gamma-aminobutyric acid)-ergic synapses (Reissner et al., 2013). Tomosyn-2 is a syntaxin 1A binding protein. Mutations within the human Neurexin1 gene are associated with neuropsychiatric conditions including developmental delay, epilepsy, autism, and schizophrenia (Harrison et al., 2011; Rabaneda et al., 2014; Reichelt et al., 2012; Reissner et al., 2013; Schaaf et al., 2012). Mutations within the human Neurexin3 gene are involved in obesity and addiction (Aoto et al., 2015). Deletion of the mouse Neurexin1 gene causes electrophysiological defects, changes in motor learning and acoustic startle reactivity that correlate with schizophrenia (Etherton et al., 2009), changed motor activity in novel environments (Grayton et al., 2013), and impaired neurotransmitter release (Pak et al., 2015).
The brain is made up of trillions of synaptic connections that together form neural networks that underpin whole brain function and behavior (Eroglu and Barres, 2010). Whether SLM2 expression impacts activity of these neural networks is unknown, but selective engineered changes in two SLM2-target Neurexin3 AS4 and Neurexin1 AS4 exons affect individual synapse function (Aoto et al., 2013; Traumnüller et al., 2016). SLM2-dependent post-synaptic responses and plasticity within CA1 pyramidal neurons can also be rescued by heterozygote deletion of the Neurexin1 AS4 exon, although individual SLM2-regulated exons are likely to have different functional effects (Aoto et al., 2013; Traumnüller et al., 2016).

Previous work showed that SLM2 expression drives regional splicing patterns across forebrain-derived structures, and that within the hippocampus SLM2 is expressed within the CA1–CA4 regions but excluded from the dentate gyrus (Ehrmann et al., 2013; Iijima et al., 2011, 2014; Traumnüller et al., 2014). Here, we find that the previously known splicing targets of SLM2 have reciprocal splicing patterns between CA1–CA3 and the dentate gyrus according to SLM2 expression levels. We hence searched for splicing changes between just the CA1–CA3 regions of wild-type and Slm2KO mice, so that any such differences would not be diluted by the splicing patterns in dentate gyrus cells that do not express Slm2. Through this analysis, we double the validated number of known SLM2-target exons and identify a potent homeostatic feedback control pathway that maintains stable Slm2 gene expression levels. Our data support a model where this feedback control pathway has evolved to maintain stable neural network activity and associated patterns of mouse behavior via moderating splicing control of synaptic isoforms.

RESULTS

Known SLM2-Target Exons Are Differentially Controlled between the Dentate Gyrus and CA1–CA3 Regions of the Hippocampus

Since SLM2 protein spatially controls splicing patterns over different brain regions (Ehrmann et al., 2013), we predicted that SLM2 expression might regionally control splicing within the hippocampus between the CA1–CA4 and the dentate gyrus, corresponding to endogenous patterns of protein expression (shown schematically in Figure 1A). We tested this prediction by analyzing regional splicing patterns of known SLM2-target exons between the CA1–CA4 and the dentate gyrus (Ehrmann et al., 2013; Iijima et al., 2011, 2014; Traumnüller et al., 2014). We hence searched for splicing changes between just the CA1–CA3 regions of wild-type and Slm2-null mice, so that any such differences would not be diluted by the splicing patterns in dentate gyrus cells that do not express Slm2. Through this analysis, we double the validated number of known SLM2-target exons and identify a potent homeostatic feedback control pathway that maintains stable Slm2 gene expression levels. Our data support a model where this feedback control pathway has evolved to maintain stable neural network activity and associated patterns of mouse behavior via moderating splicing control of synaptic isoforms.
Figure 2. SLM2 Protein Auto-regulates the 3' End of Its mRNA

(A) Genomic structure of the mouse Slm2 gene, and a variant EST AK014353 that has two additional downstream exons downloaded as a screenshot from the UCSC genome browser (Rosenbloom et al., 2015). Exons are numbered 1–11: notice that the Refseq gene has nine annotated exons, and mRNA AK014353, which is transcribed from the same locus, has 11 annotated exons.

(legend continued on next page)
predicted that it would be easier to detect splicing changes within the Slm2 knockout hippocampus by comparing CA1–CA3 transcriptomes, rather than comparing a mixture of dentate gyrus and CA1–CA3 transcriptomes. We thus carried out specific RNA sequencing (RNA-seq) analysis of the CA1–CA3 regions of the hippocampus from wild-type and Slm2 knockout (KO) mouse CA1–CA3 regions (GEO accession number GSE70895). Although we still found splicing changes in a relatively small number of exons in the Slm2 KO mouse, we validated nine targets by RT-PCR, five of which had not previously been described, thus doubling the number of known Slm2 target exons (Figure 1E).

**Mouse SLM2 Protein Regionally Controls Its Own mRNA Processing across the Brain**

We observed a decreased inclusion of Slm2 exon 9 in the Slm2 KO compared to the wild-type mouse background (Figure 1E). Note Slm2 exon 2 is also missing from the Slm2 KO transcriptome, as this exon was deleted to make the Slm2 knockout). The overall gene structure of mouse Slm2 is illustrated in Figure 2A (Rosenbloom et al., 2015). Visual analysis of the RNA-seq reads mapping to Slm2 exon 9 indicated a discontinuity in the RNA-seq profile of wild-type but not Slm2 KO mice (Figures 2B and 2C, with the position of discontinuity shown as an asterisk). While exon 9 is annotated as the terminal exon of the Slm2 gene, there is also mRNA sequence evidence (Rosenbloom et al., 2015) for two additional downstream non-coding exons that are spliced onto an internal 5’ splice site within the Slm2 exon 9 (Figures 2A and 2B). The two Slm2 exons downstream of exon 9 are annotated as exons 10 and 11, and the resulting downstream alternative mRNA 3’ end as Slm2 alternative end 2 (Figure 2B). The position of the discontinuity in RNA-seq reads within the wild-type mouse corresponds exactly to the location of the alternative 5’ splice site that leads to creation of Slm2 alternative 3’ end 2 (Figure 2C). The mRNA reads corresponding to Slm2 mRNA exons 10 and 11 were more abundant in the wild-type mouse traces compared with the Slm2 knockout mouse (Figure 2B).

**SLM2 Regulates Its Own mRNA via a Concentration-Dependent Feedback Loop**

Confirming these downstream exons are also physically spliced onto Slm2 mRNA, RT-PCR analysis using a forward primer in exon 8, and reverse primers in exon 9 (downstream of the 5’ splice site) and exon 11 detected two products within the mouse brain (Figure 2D). Parts of the brain known to express higher levels of SLM2 protein (Ehrmann et al., 2013) also express more Slm2 alternative 3’ end 2 (these were the hippocampus, cortex, basal ganglia, thalamus, and hypothalamus) (Figures 2D–2F). Physiological selection of Slm2 alternative 3’ end 2 within each brain structure was decreased from Slm2 knockout animals compared with wild-type (Figures 2E and 2F).

PhastCons analysis (Rosenbloom et al., 2015) shows that exons 9–11 of the Slm2 gene are within highly conserved regions of the mouse genome (Figure 2B). Human, mouse, and chicken SLM2 genes have an identical arrangement of exons (with two alternative 3’ ends created by alternative utilization of a 5’ splice site within exon 9, Figure 3A). Each genome region also contained multiple UAAA and UUAA sequences that could be bound by SLM2. In each case, these sequences were specifically depleted from the portion of exon sequence immediately upstream of the exon 9 internal 5’ splice site that becomes spliced onto the downstream 3’ UTR exons. Tissue-specific use of SLM2 alternative end 2 in the brain and testis, where SLM2 is highly expressed, was also detectable within RNA-seq reads from humans and chickens so must predate the divergence of the lineages leading to mammals and birds (Figures S1A–S1E).

To test whether selection of human SLM2 mRNA alternative 3’ end 2 could be induced by increased SLM2 protein expression, we engineered a stable human HEK293 cell line that expresses a human SLM2-FLAG fusion protein in response to tetracycline addition. Western blots showed that expression of SLM2-FLAG protein within this engineered cell line was efficiently induced after 24 hours of tetracycline treatment (Figure 3B). Since formation of SLM2 alternative end 2 involves the splicing of two downstream non-coding exons onto the SLM2 mRNA, we postulated that SLM2 mRNA would be a substrate for nonsense-mediated decay (NMD). RT-PCR was used to detect endogenous human SLM2 mRNAs (Figure 3C). Consistent with SLM2 mRNAs with alternative end 2 being an unstable mRNA population that is normally targeted for destruction through nonsense-mediated decay, human SLM2 mRNA isoforms with alternative end 2 were induced by overexpression of SLM2 protein, and strongly stabilized by the addition of cycloheximide (Figure 3C, compare lanes 3 and 6). Only low levels of SLM2 mRNA isoforms with alternative end 2 could be detected in the absence of cycloheximide, even after overexpression of SLM2 protein (Figure 3C, compare lines 5 and 6), although SLM2 alternative end 1 was efficiently detected.

**Sam68 Protein Also Regulates Itself via an NMD Pathway**

The above data showed that SLM2 protein auto-regulates its expression levels through an NMD pathway that is closely linked to splicing selection of an alternative 3’ end within the terminal coding exon of the Slm2 gene. However, given the low levels

---

(B) CA1–CA3 RNA-seq patterns at the downstream end of the Slm2 gene from Slm2 KO and wild-type mice aligned to the mouse genome: notice the use of additional exons 10 and 11 in the wild-type mouse genome that generate Slm2 alternative end 2. Single representative RNA-seq tracks are shown here as a screenshot from the UCSC genome browser (Rosenbloom et al., 2015).

(C) RNA-seq traces predict use of the internal splice site in Slm2 exon 9 in wild-type mouse only (the position of the exon 9 internal 5’ splice site in the RNA-seq trace is indicated by a red asterisk).

(D) Representative agarose gel showing patterns of alternative Slm2 3’ ends in different brain structures from wild-type and Slm2 KO mouse.

(E) Mouse brain structures analyzed for mRNA processing patterns.

(F) Mean percentage selection of Slm2 alternative end 2 in different brain structures from wild-type and Slm2-null mice. Statistical analyses (t tests) were carried out using GraphPad, using RT-PCR data collected from capillary gel electrophoretic analysis of three independent replicates. Error bars represent SEM. See also Figure S1.
of expression of endogenous human SLM2 protein in HEK293 cells, particularly relative to the induced SLM2-FLAG protein, we were unable to monitor whether this feedback pathway reduced the expression of endogenous human SLM2 protein, or see consistent stabilization after small interfering RNA (siRNA) depletion of the UPF1 protein that is involved in mRNA surveillance and degradation (data not shown). We thus examined the more generally expressed Sam68 locus on the UCSC genome browser (Rosenbloom et al., 2015) and found a similar arrangement of downstream non-coding exons that are spliced onto a proportion of Sam68 mRNAs to produce similar alternative ends to SLM2 (annotated as 1 and 2 on Figure S2 A). We therefore constructed a stable HEK293 cell line in which a SAM68-FLAG fusion protein was expressed in response to tetracycline addition. Induction of Sam68 protein and addition of cycloheximide strikingly increased the levels of endogenous Sam68 mRNA alternative 3' end 2 (Figure S2 B, compare lanes 5 and 6). Addition of cycloheximide also stabilized endogenous Sam68 mRNA terminating in alternative end 2 in the control cell line that did not overexpress Sam68 protein, albeit at lower levels (Figure S2 B, compare lanes 2 and 3). Supporting these data, we also observed strong stabilization of the endogenous Sam68 alternative end 2 transcript within the Sam68-overexpressing cell line as compared to a control cell line (made with empty pCDNA3 vector), detected using α-FLAG antibodies (α-actin used as a loading control).

We therefore constructed a stable HEK293 cell line in which a SAM68-FLAG fusion protein was expressed in response to tetracycline addition. Induction of Sam68 protein and addition of cycloheximide strikingly increased the levels of endogenous Sam68 mRNA alternative 3' end 2 (Figure S2 B, compare lanes 5 and 6). Addition of cycloheximide also stabilized endogenous Sam68 mRNA terminating in alternative end 2 in the control cell line that did not overexpress Sam68 protein, albeit at lower levels (Figure S2 B, compare lanes 2 and 3). Supporting these data, we also observed strong stabilization of the endogenous Sam68 alternative end 2 transcript within the Sam68-overexpressing cell line as compared to a control cell line (made with empty pCDNA3 vector), detected using α-FLAG antibodies (α-actin used as a loading control).

These auto-regulatory pathways identified for Slm2 and Sam68 are analogous to the recently described cross-regulatory splicing control of Slm1 by SLM2 (Traummüller et al., 2014). We also found that mouse Slm1 splicing is under regional control across the mouse brain by SLM2, similar to the pattern of Slm2 auto-regulation (Figures S3 A and S3 B). However, we detected only very low levels of Sam68 alternative end 2 in the

Figure 3. Alternative 3' End Processing of SLM2 mRNA Is Modulated in Response to Increasing SLM2 Protein Concentrations Leading to mRNA Instability

(A) Distribution of potential binding sites for SLM2 protein (purple arrowheads) in the downstream portion of the SLM2 gene of human, mouse, and chicken. Exons are shown as boxes. The canonical mRNA 3' end is shown in red with its normal poly(A), and the alternative 3' end (AS) in blue.

(B) Western blot showing tetracycline-induction of SLM2-flag tagged protein within a stable HEK293 cell line as compared to a control cell line (made with empty pCDNA3 vector), detected using α-FLAG antibodies (α-actin used as a loading control).

(C) Agarose gel showing induction of SLM2 alternative end 2 is induced by tetracycline treatment and stabilized by cycloheximide treatment. See also Figure S2.
SLM2 Expression Controls Splicing of a Wider Panel of Genes Implicated in Synaptic Function

Strikingly, apart from the auto-regulatory SLM2 splicing event, the other significant splicing changes identified by RNA-seq between wild-type and SLM2 knockout CA1–CA3 also affected proteins with known roles at the synapse (Table S1). These included the four previously identified SLM2 targets: Neurexin1-3 AS4 exons and an exon in the Tomosyn-2 gene (also known as STXBPSL, or Syntaxin Binding Protein 5 like). These four targets had strongly increased percentage splicing inclusion (PSI) in the SLM2 knockout background (Figure 1D) (Ehrmann et al., 2013; Traummüller et al., 2016). Newly discovered cassette exons displaying increased splicing inclusion in the SLM2 knockout background were also experimentally verified within the Dgkb (encoding the Diacylglycerol kinase beta subunit) and Kif21a (encoding kinesin family member 21a) genes (Figures 4A and 4B). SLM2 knockout mice also showed decreased inclusion of cassette exons within the LysoPLD/ATX gene (Lysophospholipase D/Autotaxin, also known as ENPP2) and the Cask gene (encoding Calcium/Calmodulin Dependent Serine Protein Kinase) (Figures 4C and 4D).

The SLM2-controlled alternative exons in the Kif21a and Cask genes have adjacent alternative exons, resulting in more complex patterns of products after RT-PCR (Figures 4A and 4C). Kif21a is a direct target of both SLM2 and Sam68, since transfection of a Kif21a minigene containing the regulated exon and flanking intron sequences into HEK293 cells along with either SLM2 or Sam68 resulted in increased exon splicing compared to co-expression of GFP (Figure 4G, lanes 1–3). Splicing of both Kif21a and LysoPLD/ATX was also differentially regulated between the CA1–CA3 and dentate gyrus/CA4 (Figures 4E and 4F), showing these exons are regionally controlled within the hippocampus.

Analysis of the mouse genome sequence revealed UAAA and UAUA sequences that could be recognized by SLM2 and Sam68 proteins flanking the newly identified target exons (Feracci et al., 2016; Rosenbloom et al., 2015), similar to those that flank the previously known Neurexin1-3 AS4 and Tomosyn-2 cassette exons (Figure 5A). We confirmed binding of SLM2 to these UWAA-rich sequences by gel shift (Figure 5B). In comparison, no shift was observed for the negative control RNA probe, representing an adjacent region of the Kif21a intron (Figure 5B). At least some of these sites are functional in splicing control, since mutation of the UWAA binding sites flanking the Kif21a exon minigene totally blocked splicing repression by SLM2-GFP and Sam68-GFP proteins in co-transfected HEK293 cells (Figure 4G, lanes 4–6).
SLM2 Protein Is Important for Synaptic Connectivity in the Mouse Hippocampus and Dentate Gyrus

Immunofluorescent localization within the hippocampal strata radiatae (sr), pyramidale (sp), and oriens (so), indicated that the majority of parvalbumin (abbreviated PV) positive interneurons within CA3 express nuclear SLM2 protein (arrowheads in Figure 6A). Nearly all of the larger, excitatory glutamatergic pyramidal cells in the CA3 fields of the hippocampus also strongly express SLM2 protein, identified by their large nuclei, and by their location in the stratum pyramidale. SLM2/NPNF (non-phosphorylated neurofilament) positive pyramidal cells are indicated by arrowheads in Figure 6B. Very few large nuclei, identified by DAPI counterstaining, were generally small and mostly belonged to glial cells, but could also be interneuronal or small pyramidal cell nuclei. These data are also consistent with results from within the CA1 subfield (Iijima et al., 2014).

Synaptic interactions between glutamatergic pyramidal cells and fast spiking (FS) inhibitory interneurons generate network activity in vivo called γ (gamma) oscillations within cortical microcircuits (Figure 6C) (Mann et al., 2005). Since patterns of γ oscillation can be disrupted in schizophrenic patients (Basar-Eroglu et al., 2007) and deletions of the human Neurexin1 gene are associated with schizophrenia (Gauthier et al., 2011), we tested whether SLM2 protein controlled the activity of these microcircuits. Extracellular LFP (local field potential) recordings of γ oscillations were conducted in stratum radiatum of the CA3 subfield of the hippocampus following the bath application of 50 nM kainate, and the induced oscillation was analyzed (n = 4 SLM2 knockout mice and five wild-type littermates) (Figure 6D). At concentrations of 50 nM kainate, the power of γ oscillations in CA3 was significantly larger in slices from wild-type (WT) mice than in slices from SLM2 knockout (KO) mice. Maximal integral power (20–80 Hz) for WT slices was 1,013.7 ± 342.6 μV²/Hz (n = 12 slices) and in slices from the SLM2 KO mice 251.9 ± 34.2 μV²/Hz (n = 10 slices; p < 0.05). The mean peak frequency of CA3 γ oscillations was not significantly different at concentrations of 50 nM kainate (WT 33.1 ± 1.6 Hz versus SLM2 KO 36.9 ± 2.6 Hz; p > 0.05).

Since the Neurexin genes are associated with epilepsy, we also monitored neuronal network excitability in the SLM2-null compared to wild-type CA3 regions at higher concentrations of...
kainate (200 nM). In wild-type mice, high amplitude burst discharges (epileptiform activity) co-existed with ongoing γ oscillations. However, this epileptiform activity was reduced by 50% in Slm2 knockout mice brain slices compared to wild-type (Figure S4). Only 25% Slm2 KO mouse slices exhibited epileptiform activity. This suggests the impairment of synaptic function and/or expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on PV interneurons in the Slm2 KO.

Immunofluorescence analysis showed that SLM2 protein also localized within pyramidal and interneuron cell types within layers II and III of the entorhinal cortex (abbreviated EC, Figures S5A and S5B). Bath application of kainate (200–400 nM) produced persistent γ frequency oscillation with the largest power of activity exhibited in the superficial layers (II/III) of the medial entorhinal cortex (mEC). In the presence of 200 nM kainate, the power of mEC γ oscillations was significantly larger in the WT slices than slices obtained from Slm2 KO mice (Figure S5C). Maximal integral power for WT slices was $341.3 \pm 85.5 \text{ mV}^2/\text{Hz}$ (n = 9 slices) and in slices from the Slm2 KO mice $44.3 \pm 16.9 \text{ mV}^2/\text{Hz}$ (n = 9 slices; p < 0.05). In contrast to the

normally; otherwise, data are expressed as the median (interquartile range). Power spectra were constructed offline from digitized data (digitization frequency, 10 kHz), using a 60-s epoch of recorded activity. Experiment and data analysis was performed by an individual who was blind to the origin of the slices. See also Figures S4 and S5.
ANOVA: F(1, 14) = 10.83; p = 0.005). This reduced motor activity.

**Slm2 KO Mice Display Increased Anxiety and Impaired Memory Abilities**

Since both neurexins and aberrant patterns of cortical γ oscillation activity have been implicated in the sensory and perceptual deficits observed in psychiatric disease, we tested a measure of sensory coding processes in the Slm2-null mouse. No difference between wild-type mice and Slm2 knockout mice were observed in a prepulse inhibition test (PPI), which measures sensimotor gating, reflecting the ability of the animals to integrate and inhibit sensory and information (females: prepulse tone p < 0.0001, genotype p = 0.678, interaction p = 0.6427. Males: pre-pulse tone p < 0.0001, genotype p = 0.053, interaction p = 0.5911) (Figures S6A and S6B).

Last, we probed Slm2-null mice for behavioral and cognitive functions. Elevated maze and open-field tasks were used to assess anxiety-related behavior. Time spent in the open arms of the elevated maze was slightly but not significantly (p > 0.05) reduced in Slm2 knockout mice (82.77 ± 57) as compared to wild-type controls (99.76 ± 69), thereby suggesting increased anxiety behavior in these mice (Figure 7A). To further explore this possibility, mice were subjected to an open-field test. In this task, we used as indexes of anxiety behavior both general exploratory activity of mice and the time they spent in center versus periphery of a squared arena. As shown in Figures 7B and 7C, Slm2 knockout mice traveled shorter distance as compared to wild-type (average distance: 2,233 ± 350 cm in Slm2 knockout mice and 3,464 ± 189 cm in WT mice; one-way ANOVA: F(1,14) = 10.83; p = 0.005). This reduced motor activity was due to a locomotor defect, as assessed by rotarod test (Figures S6C and S6D). Also, we found that Slm2-null mice spent less time in the central region of the arena (Figures 7C and 7D) as compared to wild-type (time spent in center: 11% in Slm2 knockout mice and 21% in wild-type mice; one-way ANOVA: F(1,7) = 15.32; p < 0.005). Together, these data indicate that Slm2-null mice display increased anxiety-related behaviors.

Reduction in cortical γ oscillations has been associated with defects of mouse behavior in the non associative exploratory task of novel object recognition (NOR) (Lee et al., 2014). We thus probed memory abilities in Slm2-null mice using this task, which consisted of exposing them to one previously presented object (Familiar Object, FO) together with an unfamiliar object (Novel Object, NO) (Figure 7B). Since mice have innate preference toward novelty, prominent NO exploration is an index of recognition of this object as different from FO. To avoid any bias in the interpretation of behavioral data due to reduced exploratory behavior in Slm2 KO mice (Figures 7B–7D), we measured the preference index for NO (time spent in contact with NO versus FO), which represents a valuable measure for increased exploration toward NO regardless of general level of exploration. Strikingly, Slm2 KO mice showed no increased interest toward NO (Preference index 50%; one-way ANOVA between genotypes: F(1,18) = 4.24, p = 0.016) (Figure 7E), which is indicative of impaired recognition memory in Slm2 KO mice.

**DISCUSSION**

Here, we have sequenced RNA from just the SLM2-expressing portion of the hippocampus to identify RNA processing pathways controlled by this protein. We find that SLM2 auto-regulates, controls an expanded set of alternatively spliced exons within genes exclusively encoding synaptic proteins, and is required for normal electrophysiological and behavioral functions. Auto-regulatory pathways have been described for a
number of splicing regulator proteins where they play an important role in splicing factor homeostasis and likely maintain stable transcriptomes (Jangi and Sharp, 2014), but the physiological importance of these feedback pathways are not usually well understood. In contrast, the identification of an SLM2 auto-regulatory feedback loop here, along with its other targets being a restricted group of synaptic protein isoforms, suggests that SLM2 levels need to be maintained within tight windows for normal functioning of the nervous system. A similar auto-regulatory pathway also controls Sam68, which regulates some of the same synaptic protein isoforms as SLM2, including the Neurexin1 and Neurexin3 AS4 exons. Hence, these feedback pathways were likely present in the ancestral gene that tripped to give the current SLM2, Sam68, and SLM1 genes. These feedback pathways would fine-tune expression of these splicing regulators to ensure stable physiological splicing patterns for the Neurexin genes, and the maintenance of normal patterns of synaptic connectivity.

Our data also indicate that neurons within the hippocampus regionally utilize different isoforms generated by alternative splicing control according to SLM2 protein concentrations. Electrophysiological measurements of neural network activity indicate that SLM2 protein levels affect interactions between electrically coupled pyramidal cells and interneurons (Buzsáki et al., 2013; Traub et al., 2004). In vivo, γ oscillations have been shown to be important for various cognitive tasks such as working memory (Howard et al., 2003), attention (Fries et al., 2001), and perception (Gray et al., 1989). Genome engineering to suppress alternative splicing of the Neurexin3 AS4 exon alone caused reduced excitatory AMPA post-synaptic receptor accumulation, although N-methyl-D-aspartate (NMDA) receptors remained unchanged (Aoto et al., 2013). Reduced post-synaptic AMPA receptors would impact upon the AMPA-mediated phasic drive onto PV interneurons (in the form of excitatory post-synaptic potentials) that is required to activate these FS interneurons and their subsequent phasing of pyramidal cells during γ oscillations (Tamás et al., 2000; Whittington et al., 1995). Thus, changes in Neurexin AS4 splicing patterns, which were the highest amplitude splicing changes detected in the Slm2 KO hippocampus, could directly influence patterns of γ frequency oscillations. We also detected altered splicing from the CASK gene, which encodes an important scaffolding trans-membrane protein kinase that interacts with and phosphorylates Neurexin proteins (Mukherjee et al., 2008). The impaired γ-oscillations registered in the Slm2 KO brain may also be impacted by altered Tomosyn2 splicing that could affect Tomosyn2 protein stability (Williams et al., 2011). Tomosyn2 controls acetyl choline release from cholinergic nerve terminals (Geerts et al., 2015) and acetylcholine (ACH) is known to induce persistent γ-oscillations in the hippocampus (Picciotto et al., 2012). LysoPLD/ATX encodes one of the major enzymes involved in synthesis of lysophosphatidic acid (LPA), a molecule with a key signaling role controlling both excitatory and inhibitory synapse functions (García-Morales et al., 2015; Vogt et al., 2015). LPA has a critical role in the nervous system: knockout of LPA1 receptor causes anxiety (Santin et al., 2009), which also characterizes the Slm2 mouse, and LysoPLD/ATX is essential for brain development (Greenman et al., 2015). An LPA1-deficient mouse was also observed to display reductions in γ oscillations, albeit in the entorhinal cortex and not the hippocampus (Cunningham et al., 2006).

Disruptions in γ oscillations within the hippocampus and the adjacent entorhinal cortex affect forms of learning in which a novel object has to be stored and later recalled (Lee et al., 2014), and Slm2-null mice were defective in such novel object recognition. Our results indicate that proper function of circuits involved in spatial recognition of novel cues is impaired in the absence of SLM2. SLM2 protein is widely expressed across different brain structures, suggesting that its loss might cause global defects, but Slm2-null mice have no general locomotor problems, as assessed in the open-field test, nor in the rotorod assay. This last test is particularly significant, since decreased motor coordination can be detected in Sam68-null mice using a rotorod test (Iijima et al., 2011), indicating a clear phenotypic difference between these two very similar related proteins.

**EXPERIMENTAL PROCEDURES**

**RNA-Seq Analysis**

Paired-end sequencing was done in total for six samples on an Illumina Hiseq 2000 machine (three biological replicates of wild-type and Slm2 knockout CA1–CA3 regions. RNA-seq data were mapped using STAR (Dobin et al., 2013), and splicing changes were analyzed using MAJIO (Vaquero-García et al., 2018).

**Detection of Splicing Patterns in Mouse Tissues**

Alternative mRNA isoforms were measured in total RNA prepared from different mouse brain structures, using RT-PCR and standard conditions, with primers provided in Supplemental Experimental Procedures. Reactions were quantitated by capillary gel electrophoresis and splicing profiles were calculated as percentage splicing inclusion (PSI).

**Generation, RNA Preparation, and PCR from Tetracycline-Inducible HEK293 Cells**

To generate the inducible cell lines, the SLM2-FLAG-pCDA5 and Sam68FLAG-pCDA5 plasmids were individually cotransfected with the Fip recombinase plasmid (pOG44) into Flp-In HEK293 cells and selected with Hygromycin B (full details in Supplemental Experimental Procedures). SLM2-FLAG and SAM68-FLAG were induced by tetracycline. RNA was prepared from the cells at time 0 and 24 hr after tetracycline induction, 24 hr after tetracycline addition, either 50 μg/mL cycloheximide or ethanol was added to the cells for 4 hr. cDNA was prepared with Superscript III (Invitrogen) and DNase-treated RNA.

**Minigene Experiments**

The Kif21a exon and flanking intron sequences were PCR amplified from mouse genomic DNA and cloned into pXJ41 (Bourgeois et al., 1999). Splicing patterns were monitored after transfection into HEK293 cells with expression constructs encoding GFP, SLM2-GFP, or Sam68-GFP as previously described (Ehrmann et al., 2013).

**Whole-Animal Work**

Behavioral assays were carried out according to standard protocols as described in Supplemental Experimental Procedures.

**Immunofluorescence**

SLM2 was localized within the mouse hippocampus and entorhinal cortex using indirect immunofluorescence, according to standard protocols described in Supplemental Experimental Procedures.
In Vitro Brain Slice Electrophysiology

All procedures were performed according to the requirements of the United Kingdom Animals Scientific Procedures Act (1986) according to the protocols described in Supplemental Experimental Procedures.

ACCESSION NUMBERS

The accession number for the data sets reported in this paper is GEO: GSE70895 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70895).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and one table and can be found with this article online at http:// dx.doi.org/10.1016/j.celrep.2016.12.002.

AUTHOR CONTRIBUTIONS

Conceptualization, I.E., Y.B., G.J.C., S.M., C.S., M.C., and D.J.E.; Investigation, I.E., D.J.E., M.R.G., V.P., T.V., I.E., D.J.E.; Writing – Review and Editing, I.E., M.R.G., V.P., T.V., F.P., C.S., G.J.C., Y.B., and M.C.; Writing – Original Draft, D.J.E.; Writing –Review and Editing, I.E., M.R.G., V.P., T.V., F.P., C.S., G.J.C., Y.B., and M.C.; Funding Acquisition, D.J.E., Y.B., C.S., and S.M.; Resources, M.K.-G., M.M., and M.S.-K.; Supervision, M.S.-K. and T.V.

ACKNOWLEDGMENTS

This work was funded by the BBSRC (grant numbers BB/K018957/1 and BB/I006923/1); Telethon (GP14095) and A IRC (IG14851); the EC FP7 funded INFRAFRONTIER-I3 project (grant number 312325); and by NIH grant R01 AG048544 to Y.B. and a pilot grant to Y.B. from Penn Medicine Neuroscience Centre. We thank Rachel Morgan for help refining graphical images.

Received: May 13, 2016
Revised: October 25, 2016
Accepted: November 29, 2016
Published: December 20, 2016

REFERENCES

Aoto, J., Martiniell, D.C., Malenka, R.C., Tabuchi, K., and Sudhof, T.C. (2013). Presynaptic neurexin-3 alternative splicing trans-synaptically controls post-synaptic AMPA receptor trafficking. Cell 154, 75–88.
Aoto, J., Földy, C., Ilics, S.M., Tabuchi, K., and Sudhof, T.C. (2015). Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses. Nat. Neurosci. 18, 997–1007.
Basar-Eroglu, C., Brand, A., Hildebrandt, H., Karolina Kedzior, K., Mathes, B., and Schmidt, C. (2007). Working memory related gamma oscillations in schizophrenia patients. Int. J. Psychophysiol. 64, 39–45.
Bourgeois, C.F., Popielarz, M., Hildewein, G., and Stevenin, J. (1999). Identification of a bidirectional splicing enhancer: Differential involvement of SR proteins in 5’ or 3’ splice site activation. Mol. Cell. Biol. 19, 7347–7356.
Buzsáki, G., Logothetis, N., and Singer, W. (2013). Scaling brain size, keeping timing: Evolutionary preservation of brain rhythms. Neuron 80, 751–764.
Cunningham, M.O., Hunt, J., Middleton, S., Lébeau, F.E., Gillies, M.J., Davies, C.H., Maycox, P.R., Whittington, M.A., and Racca, C. (2006). Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J. Neurosci. 26, 2767–2776.
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012). Landscape of transcription in human cells. Nature 498, 101–108.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21.
Ehrmann, I., Dalgleish, C., Liu, Y., Danilenko, M., Crosier, M., Overman, L., Arthur, H.M., Lindsay, S., Clowry, G.J., Venables, J.P., et al. (2013). The tissue-specific RNA binding protein T-STAR controls regional splicing patterns of neurexin pre-mRNAs in the brain. PLoS Genet. 9, e1003474.
Ergul, C., and Barres, B.A. (2010). Regulation of synaptic connectivity by glia. Nature 468, 223–231.
Etherton, M.R., Blais, C.A., Powell, C.M., and Sudhof, T.C. (2009). Mouse neurexin-1 alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl. Acad. Sci. USA 106, 17998–18003.
Feracci, M., Foot, J.N., Grellscheid, S.N., Danilenko, M., Stehle, R., Gonchar, O., Kang, H.S., Dalgleish, C., Meyer, N.H., Liu, Y., et al. (2016). Structural basis of RNA recognition and dimethylation by the STAR proteins T-STAR and Sam68. Nat. Commun. 7, 10355.
Fries, P., Reynolds, J.H., Rorie, A.E., and Desimone, R. (2001). Modulation of oscillatory neuronal synchronization by selective visual attention. Science 291, 1560–1563.
García-Morales, V., Montero, F., González-Forero, D., Rodríguez-Bey, G., Gómez-Perez, J., Medialeón-Varo, M., Valle, J., Velázquez-Vas, G., García-Verdugo, J.M., and Moreno-López, B. (2015). Membrane-derived phospholipids define coordinate normal and y-amyloidosis. PLoS Biol. 13, e1002153.
Gauthier, J., Siddiquí, T.J., Huashan, P., Yokomaku, D., Hamdan, F.F., Champagne, N., Lapointe, M., Spiegelman, D., Noreau, A., Lafiore, R.G., et al. (2011). Truncating mutations in Nrxn2 and Nrxn1 in autism spectrum disorders and schizophrenia. Hum. Genet. 130, 563–573.
Geerts, C.J., Plomp, J.J., Koopmans, B., Loos, M., van der Pijl, E.M., van der Valk, M.A., Verhage, M., and Groffen, A.J. (2015). Tomosyn-2 is required for normal motor performance in mice and sustains neurotransmission at motor endplates. Brain Struct. Funct. 220, 1971–1982.
Gehman, L.T., Meera, P., Stoilov, P., Shieu, L., O’Brien, J.E., Meisler, M.H., Ares, M., Jr., Otis, T.S., and Black, D.L. (2012). The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. Genes Dev. 26, 445–460.
Gray, C.M., König, P., Engel, A.K., and Singer, W. (1989). Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature 338, 334–337.
Grayton, H.M., Missler, M., Collier, D.A., and Fernandes, C. (2013). Altered socio-cognitive behaviours in neurexin 1 knockout mice resemble core symptoms in neurodevelopmental disorders. PLoS ONE 8, e67114.
Greenman, R., Gorelik, A., Sapir, T., Baumgart, J., Zamor, V., Segal-Saloto, M., Levin-Zaidman, S., Aidonis, V., Aoki, J., Nitsch, R., et al. (2015). Non-cell autonomous and non-catalytic activities of ATX in the developing brain. Front. Neurosci. 9, 53.
Harrison, V., Connelly, V., Hayesmoore, J., McParland, J., Pike, M.G., and Blair, E. (2011). Compound heterozygous deletion of Nrxn1 causing severe developmental delay with early onset epilepsy in two sisters. Am. J. Med. Genet. A 155A, 2826–2831.
Howard, M.W., Rizzuto, D.S., Caplan, J.B., Madsen, J.R., Lisman, J., Aschenbrucker, R., Ehrmann, I., Dalgleish, C., Liu, Y., et al. (2016). Structural basis of RNA recognition and dimerization by the STAR proteins T-STAR and Sam68. Nat. Commun. 7, 10355.
Iijima, T., Iijima, Y., Witte, H., and Scheiffele, P. (2014). Neuronal cell type-specific alternative splicing is regulated by the KH domain protein SLM1. J. Cell Biol. 205, 7347–7356.
Kalsotra, A., and Cooper, T.A. (2011). Functional consequences of developmentally regulated alternative splicing. Nat. Rev. Genet. 12, 715–729.
Lee, H.S., Ghetti, A., Pinto-Duarte, A., Wang, X., Dziewczapolski, G., Galimi, F., Hutron-Renzidz, S., Piña-Crespo, J.C., Roberts, A.J., Verma, I.M., et al.
Astrocytes contribute to gamma oscillations and recognition memory. Proc. Natl. Acad. Sci. USA 111, E3343–E3352.

Mann, E.O., Radcliffe, C.A., and Paulsen, O. (2005). Hippocampal gamma-frequency oscillations: From interneurones to pyramidal cells, and back. J. Physiol. 562, 55–63.

Mukherjee, K., Sharma, M., Urlaub, H., Bourenkov, G.P., Jahn, R., Sudhof, T.C., and Wahl, M.C. (2008). CASK Functions as a Mg2+-independent neurexin kinase. Cell 133, 328–339.

Pacheco, T.R., Gomes, A.Q., Barbosa-Morais, N.L., Benes, V., Ansorge, W., Wollerton, M., Smith, C.W., Valcarcel, J., and Carmo-Fonseca, M. (2004). Diversity of vertebrate splicing factor U2AF35: Identification of alternatively spliced U2AF1 mRNAs. J. Biol. Chem. 279, 27039–27049.

Pak, C., Danko, T., Zhang, Y., Aoto, J., Anderson, G., Maxeiner, S., Yi, F., Wernig, M., and Sudhof, T.C. (2015). Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synchronous Transmission Defects Caused by Heterozygous Mutations in NRXN1. Cell Stem Cell 17, 316–328.

Picciotto, M.R., Higley, M.J., and Mineur, Y.S. (2012). Acetylcholine as a neuromodulator: Cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116–129.

Rabaneda, L.G., Robles-Lanuza, E., Nieto-González, J.L., and Scholl, F.G. (2014). Neurexin dysfunction in adult neurons results in autistic-like behavior in mice. Cell Rep. 8, 338–346.

Reichelt, A.C., Rodgers, R.J., and Clapcote, S.J. (2012). The role of neurexins in schizophrenia and autistic spectrum disorder. Neuropharmacology 62, 1519–1526.

Reissner, C., Runkel, F., and Missler, M. (2013). Neurexins. Genome Biol. 14, 213.

Rosenbloom, K.R., Armstrong, J., Barber, G.P., Casper, J., Clawson, H., Dikehans, M., Dreszer, T.R., Fujita, P.A., Guruvadoo, L., Haeussler, M., et al. (2015). The UCSC Genome Browser database: 2015 update. Nucleic Acids Res. 43, D670–D681.

Santin, L.J., Bilbao, A., Pedraza, C., Matas-Rico, E., López-Barroso, D., Castillo-Ortega, E., Sánchez-López, J., Riquelme, R., Varela-Nieto, L., de la Villa, P., et al. (2009). Behavioral phenotype of mGplA-null mice: Increased anxiety-like behavior and spatial memory deficits. Genes Brain Behav. 8, 772–784.

Vogt, J., Yang, J.W., Mobascher, A., Cheng, J., Li, Y., Liu, X., Baumgart, J., Thalman, C., Kirschuk, S., Unichenko, P., et al. (2015). Molecular cause and functional impact of altered synaptic lipid signaling due to a prg-1 gene SNP. EMBO Mol. Med. 8, 25–38.

Voineagu, I., Wang, X., Johnston, P., Lowe, J.K., Tian, Y., Horvath, S., Mill, J., Cantor, R.M., Blencowe, B.J., and Geschwind, D.H. (2011). Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380–384.

Whittington, M.A., Traub, R.D., and Jefferys, J.G. (1995). Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. Nature 373, 612–615.